ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
Provided By GlobeNewswire
Last update: Nov 13, 2024
Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024
Positive lonigutamab EOP2 FDA interaction completed and initiation of subcutaneous Phase 3 development program in thyroid eye disease (TED) expected in Q1 2025
Read more at globenewswire.com2.6
+0.43 (+19.82%)
Find more stocks in the Stock Screener
SLRN Latest News and Analysis
2 days ago - ChartmillThese stocks are moving in today's pre-market sessionLet's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.
2 days ago - ChartmillWondering what's happening in today's after-hours session?The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.
